Compare SLNG & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ALDX |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 88.1M |
| IPO Year | 2019 | 2014 |
| Metric | SLNG | ALDX |
|---|---|---|
| Price | $5.00 | $0.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 20.8K | ★ 950.4K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $68,245,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $1.07 |
| 52 Week High | $7.07 | $5.93 |
| Indicator | SLNG | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 31.33 |
| Support Level | $4.79 | N/A |
| Resistance Level | $5.52 | $1.58 |
| Average True Range (ATR) | 0.27 | 0.11 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 37.09 | 5.00 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. The company has a geographical presence in the United States and Mexico.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.